Systematic assessment in an animal model of the angiogenic potential of different human cell sources for therapeutic revascularization

Table 1 Implantation of CD34+-enriched mononuclear cells from mobilized blood or cord blood enhances vascularization in subcutaneous sponge implants without incorporation into vessels

		Vessel density (Chalkley counts)
Source	Implanted cells	Untreated	Treated	Difference	Probability level (ANOVA)	Incorporation into vessels
Mobilized peripheral blood (donors: n = 2)	CD34-enriched MNC (mice: n = 8)	3.833 (0.661)	10.250 (1.254)	6.417 (0.785)	0.00008*	No
	CD34-depleted MNC (mice: n = 8)	5.021 (1.023)	5.208 (0.465)	0.187 (0.710)	0.799	No
Umbilical cord blood (donors: n = 2)	CD34-enriched MNC (mice: n = 7)	3.929 (0.655)	7.405 (0.957)	3.476 (1.207)	0.028*	No
	CD34-depleted MNC (mice: n = 8)	3.604 (1.200)	4.437 (0.836)	0.833 (1.568)	0.603	No
Bone marrow (donors: n = 3)	CD34-enriched MNC (mice: n = 10)	6.483 (0.509)	7.433 (1.047)	0.950 (1.003)	0.368	No
	CD34-depleted MNC (mice: n = 10)		6.317 (0.752)	-0.167 (1.226)	0.895	No

Implantation of CD34⁺-enriched mononuclear cells (MNC) from granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood or umbilical cord blood significantly increased new vessel formation in subcutaneous sponges (*P < 0.05). Vessel density was increased between paired cell-impregnated sponges compared to contralateral control sponges without cells. Implantation of CD34⁺-enriched MNC from bone marrow and CD34⁺-depleted MNC from any source had no significant effect on vessel density. No human cells incorporated into vessels. Data are means, with standard errors in parentheses. Probability was determined by repeat-sample analysis of variance (ANOVA) on individual readings for each mouse from pooled data from different donors.

ISSN: 1757-6512